SAR 443809
Alternative Names: SAR-443809Latest Information Update: 21 Apr 2025
At a glance
- Originator Sanofi
- Class Monoclonal antibodies; Urologics
- Mechanism of Action Complement factor B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 31 Dec 2024 Discontinued - Phase-I for Paroxysmal nocturnal haemoglobinuria (In volunteers) in USA (IV), before December 2024
- 31 Dec 2024 Discontinued - Phase-I for Paroxysmal nocturnal haemoglobinuria (In volunteers) in USA (SC), before December 2024
- 28 Nov 2024 No recent reports of development identified for phase-I development in Paroxysmal-nocturnal-haemoglobinuria(In volunteers) in USA (IV)